Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase

Nature Chemical Biology

Volumn 11, Issue 10, 2015, Pages 779-783

  Coelho, Catarina ^a   Foti, Alessandro ^b   Hartmann, Tobias ^b   Santos Silva, Teresa ^a   Leimkühler, Silke ^b   Romão, Maria João ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b UNIVERSITY OF POTSDAM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; PHTHALAZINE DERIVATIVE; THIORIDAZINE; XENOBIOTIC AGENT; ALDEHYDE DEHYDROGENASE; AOX1 PROTEIN, HUMAN; AOX3 PROTEIN, MOUSE; ENZYME INHIBITOR; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG METABOLISM; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ESCHERICHIA COLI; GENETICS; METABOLISM; SPECIES DIFFERENCE; X RAY CRYSTALLOGRAPHY;

ALDEHYDE OXIDASE; ALDEHYDE OXIDOREDUCTASES; ANIMALS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; XENOBIOTICS;

EID: 84941876920     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1895     Document Type: Article

References (43)

1. Garattini, E., Fratelli, M. & Terao, M. The mammalian aldehyde oxidase gene family. Hum. Genomics 4, 119-130 (2009).
2. Garattini, E., Fratelli, M. & Terao, M. Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell. Mol. Life Sci. 65, 1019-1048 (2008).
3. Hille, R., Hall, J. & Basu, P. The mononuclear molybdenum enzymes. Chem. Rev. 114, 3963-4038 (2014).
4. Garattini, E., Mendel, R., Romao, M.J., Wright, R. & Terao, M. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem. J. 372, 15-32 (2003).
5. Mahro, M. et al. Identification of crucial amino acids in mouse aldehyde oxidase 3 that determine substrate specificity. PLoS ONE 8, e82285 (2013).
6. Wahl, R.C. & Rajagopalan, K.V. Evidence for the inorganic nature of the cyanolyzable sulfur of molybdenum hydroxylases. J. Biol. Chem. 257, 1354-1359 (1982).
7. Okamoto, K. et al. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc. Natl. Acad. Sci. USA 101, 7931-7936 (2004).
8. Jones, R.M., Inscore, F.E., Hille, R. & Kirk, M.L. Freeze-quench magnetic circular dichroism spectroscopic study of the "very rapid" intermediate in xanthine oxidase. Inorg. Chem. 38, 4963-4970 (1999).
9. Terao, M. et al. Avian and canine aldehyde oxidases. Novel insights into the biology and evolution of molybdo-flavoenzymes. J. Biol. Chem. 281, 19748-19761 (2006).
10. Garattini, E. & Terao, M. The role of aldehyde oxidase in drug metabolism. Expert Opin. Drug Metab. Toxicol. 8, 487-503 (2012).
11. Obach, R.S., Huynh, P., Allen, M.C. & Beedham, C. Human liver aldehyde oxidase: inhibition by 239 drugs. J. Clin. Pharmacol. 44, 7-19 (2004).
12. Pryde, D.C. et al. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J. Med. Chem. 53, 8441-8460 (2010).
13. Garattini, E. & Terao, M. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab. Rev. 43, 374-386 (2011).
14. Kitamura, S., Sugihara, K. & Ohta, S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab. Pharmacokinet. 21, 83-98 (2006).
15. Fu, C. et al. Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship. Drug Metab. Dispos. 41, 1797-1804 (2013).
16. Rashidi, M.R., Smith, J.A., Clarke, S.E. & Beedham, C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab. Dispos. 25, 805-813 (1997).
17. Beedham, C. The role of non-P450 enzymes in drug oxidation. Pharm. World Sci. 19, 255-263 (1997).
18. Beedham, C. in Drug Metabolism: Towards the Next Millenium (ed. Gooderham, N.J.) 39-52 (IOS Press, 1998).
19. Coelho, C. et al. The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity. J. Biol. Chem. 287, 40690-40702 (2012).
20. Mahro, M. et al. Characterization and crystallization of mouse aldehyde oxidase 3: from mouse liver to Escherichia coli heterologous protein expression. Drug Metab. Dispos. 39, 1939-1945 (2011).
21. Obach, R.S. & Walsky, R.L. Drugs that inhibit oxidation reactions catalyzed by aldehyde oxidase do not inhibit the reductive metabolism of ziprasidone to its major metabolite, S-methyldihydroziprasidone: an In vitro study. J. Clin. Psychopharmacol. 25, 605-608 (2005).
22. Rani Basu, L., Mazumdar, K., Dutta, N.K., Karak, P. & Dastidar, S.G. Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. Microbiol. Res. 160, 95-100 (2005).
23. Amaral, L. & Viveiros, M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int. J. Antimicrob. Agents 39, 376-380 (2012).
24. Christensen, J.B. et al. A comparative analysis of In vitro and in vivo efficacies of the enantiomers of thioridazine and its racemate. PLoS ONE 8, e57493 (2013).
25. Christensen, J.B., Hendricks, O. & Kristiansen, J. Thioridazine and derivatives thereof for reversing antimicrobial drug resistance. US patent 8,623,864 (2014).
26. Baral, P.K. et al. Structural basis of prion inhibition by phenothiazine compounds. Structure 22, 291-303 (2014).
27. Wang, A., Stout, C.D., Zhang, Q. & Johnson, E.F. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J. Biol. Chem. 290, 5092-5104 (2015).
28. Enroth, C., Eger, B.T., Okamoto, K., Nishino, T. & Pai, E.F. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc. Natl. Acad. Sci. USA 97, 10723-10728 (2000).
29. Ishikita, H., Eger, B.T., Okamoto, K., Nishino, T. & Pai, E.F. Protein conformational gating of enzymatic activity in xanthine oxidoreductase. J. Am. Chem. Soc. 134, 999-1009 (2012).
30. Schlauderer, F. et al. Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase. Angew. Chem. Int. Ed. Engl. 52, 10384-10387 (2013).
31. Wilder, P.T. et al. In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction. Int. J. High Throughput Screen. 2010, 109-126 (2010).
32. Barr, J.T. & Jones, J.P. Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab. Dispos. 39, 2381-2386 (2011).
33. Romão, M.J. Molybdenum and tungsten enzymes: a crystallographic and mechanistic overview. Dalton Trans. 21, 4053-4068 (2009).
34. Palmer, T. et al. Involvement of the narJ and mobgene products in the biosynthesis of the molybdoenzyme nitrate reductase in Escherichia coli. Mol. Microbiol. 20, 875-884 (1996).
35. Temple, C.A., Graf, T.N. & Rajagopalan, K.V. Optimization of expression of human sulfite oxidase and its molybdenum domain. Arch. Biochem. Biophys. 383, 281-287 (2000).
36. Hartmann, T. et al. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab. Dispos. 40, 856-864 (2012).
37. Leslie, A.G.W. & Powell, H.R. Evolving Methods for Macromolecular Crystallography (eds. Read, R.J. & Sussman, J.L.) 41-51 (Springer, 2007).
38. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
39. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72-82 (2006).
40. McCoy, A.J., Grosse-Kunstleve, R.W., Storoni, L.C. & Read, R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61, 458-464 (2005).
41. Schwarzenbacher, R., Godzik, A., Grzechnik, S.K. & Jaroszewski, L. The importance of alignment accuracy for molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 60, 1229-1236 (2004).
42. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
43. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).